Physician profile
Michael R Solinger
NPI 1518944305
$951.03
in general payments reported to CMS, 2019-2025
17 companies · $88.50 in 2025
The $88.50 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.49 · 2022: $400 · 2023: $258 · 2024: $122 · 2025: $88.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $149.96 | 2023 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.22 | 2021-2022 | |
| Abbvie INC. | $112.61 | 2021-2025 | |
| Janssen Biotech, INC. | $95.66 | 2022-2025 | Tremfya |
| Aimmune Therapeutics, INC. | $86.68 | 2024 | |
| Celgene Corporation | $62.50 | 2023 | Zeposia |
| Daiichi Sankyo INC. | $56.93 | 2022 | |
| Nestle Healthcare Nutrition INC. | $45.51 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.76 | 2022 | |
| Genzyme Corporation | $29.12 | 2022 | |
| Olympus America INC. | $28.42 | 2021-2024 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Madrigal Pharmaceuticals | $22.22 | 2025 | Rezdiffra |
| Capsovision, INC. | $21.54 | 2024 | Capsocam Plus |
| Pfizer INC. | $17.23 | 2025 | |
| Qol Medical, LLC | $13.07 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.29 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Solinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.